Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Shares Issued (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Shares Issued for 9 consecutive years, with $66.4 million as the latest value for Q2 2025.

  • On a quarterly basis, Shares Issued changed N/A to $66.4 million in Q2 2025 year-over-year; TTM through Dec 2025 was $66.4 million, a 56.37% increase, with the full-year FY2025 number at $66.4 million, up 56.37% from a year prior.
  • Shares Issued was $66.4 million for Q2 2025 at Akebia Therapeutics, up from $78000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $72.4 million in Q4 2021 to a low of -$6.7 million in Q4 2022.
  • A 5-year average of $17.6 million and a median of $6.3 million in 2022 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: crashed 109.27% in 2022, then skyrocketed 2209200.0% in 2024.
  • Akebia Therapeutics' Shares Issued stood at $72.4 million in 2021, then crashed by 109.27% to -$6.7 million in 2022, then surged by 100.01% to $1000.0 in 2023, then surged by 2209200.0% to $22.1 million in 2024, then surged by 200.42% to $66.4 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Shares Issued are $66.4 million (Q2 2025), $78000.0 (Q1 2025), and $22.1 million (Q4 2024).